Triumeq is a fixed-dose combination formulation containing dolutegravir (an integrase strand transfer inhibitor), abacavir, and lamivudine (both nucleoside reverse transcriptase inhibitors). It is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kilograms.
Dosage and Administration, Recommended Dose of Triumeq
Adult Patients
Dose: One tablet once daily.
Administration Time: May be taken with or without food.
Dosage Form Selection: Only Triumeq tablets should be used; Triumeq PD oral suspension tablets are not to be used.
Pediatric Patients
6 kg to <10 kg: 3 tablets of Triumeq PD once daily.
10 kg to <14 kg: 4 tablets of Triumeq PD once daily.
14 kg to <20 kg: 5 tablets of Triumeq PD once daily.
20 kg to <25 kg: 6 tablets of Triumeq PD once daily.
≥25 kg: 1 tablet of Triumeq once daily.
Dosage Specifications
Triumeq tablets: Each tablet contains 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine.
Dose Adjustment of Triumeq
Dose Adjustment in Patients with Hepatic Impairment
Mild hepatic impairment (Child-Pugh Class A): If a reduction in abacavir dose is required, single-component preparations should be used.
Moderate or severe hepatic impairment (Child-Pugh Class B or C): Contraindicated.
For patients with hepatitis B, discontinuation of lamivudine-containing products may result in a severe acute exacerbation of hepatitis B. Close monitoring of liver function is required, and anti-hepatitis B treatment should be initiated if necessary.
Dose Adjustment for Concomitant Medication
When used concomitantly with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampicin, the dose of dolutegravir needs to be adjusted.
Adults and pediatric patients weighing ≥25 kg: The dose of dolutegravir should be adjusted to 50 mg twice daily.
An additional 50 mg tablet of Tivicay (dolutegravir) needs to be taken 12 hours apart from Triumeq.
Use of Triumeq in Special Populations
Pediatric Patients
Eligibility Criteria: Pediatric patients aged at least 3 months and weighing at least 6 kilograms.
Not Recommended For: Pediatric patients younger than 3 months or weighing less than 6 kg, as well as children with renal or hepatic impairment.
Patients with Renal Impairment
Contraindication: Patients with a creatinine clearance <30 mL/min.
Pediatric patients with a similar degree of renal impairment based on age-appropriate renal function assessment.
Geriatric Patients
No dose adjustment is required for geriatric patients.
The possibility of decreased hepatic, renal, or cardiac function in geriatric patients should be taken into consideration.
